

SUBLIMED

One line pitch:

SUBLIMED is developing actiTENS®, an innovative and connected medical device for chronic pains management, based on a proven non-drug therapy.

Market Analysis:

SUBLIMED develops a medical device and targets the neuropathic chronic pain market, which concerns more than 300 million people worldwide. The SUBLIMED medical device is based on a proven non-drug therapy, the transcutaneous electrical nerve stimulation (TENS). Pharmaceutical industries capture 90% of the market. Nevertheless, medicine based treatments present several disadvantages, in particular a high level of costs, unwanted adverse effects, addiction and low efficacy. One figure is particularly relevant to illustrate the importance of the TENS in chronic pain management : in the US, 32% of people following a rehabilitation therapy and suffering from chronic pains are treated by TENS.

Value proposition:

The conventional TENS devices take the shape of a voluminous casing (hand carried, attached to the belt or worn around the neck), tied with cutaneous electrodes through long cables causing physical and psychological embarrassment which highly compromises the adoption of the TENS by patients. actiTENS® offers a miniaturized, thin and flexible device, which is directly worn on the body, and adapts itself perfectly to the morphology of each patient. Easily hidden under clothes, monitored wirelessly by smartphone, actiTENS® discreetly supports patient in daily activities, brings physician useful information to evaluate the efficacy of the therapy and allows him to refine and adapt treatment.

Business Model:

SUBLIMED business model is based on sales of TENS devices and disposable electrodes. We are also currently developing an algorithm based on all the data collected through actiTENS® app. This innovative service will help physician to refine and improve the treatment for a given patient and will allow him to save time. We are currently evaluated a complementary business model in which this service will be sold to pain treatment centre.

IP and Regulatory situation:

SUBLIMED signed with the French Alternative Energies and Atomic Energy Commission (CEA) an exclusive and worldwide licence agreement on 5 patents protecting the SUBLIMED innovative products. A first freedom to operate analysis has been done with the CEA support and no blocking point has been found.



SUBLIMED

COMPANY PROFILE

- **Website:**
<http://subli-med.com/>
- **Field:**
- **Contact:**
KARST Nicolas
nicolas.karst@subli-med.com
- **Location:**
9, rue du rocher de lorzier
38430 MOIRANS
France
- **Founded in:** //10/2015
- **Employees:** 5
- **Financial information (€):**
 - **Company stage:**
Pilot Phase
 - **Capital raised to date:**
711 000
 - **Monthly burn rate:**
 - **Capital seeking and date:**
- **Investors:**